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Ror2 is an orphan receptor tyrosine kinase with expression
normally restricted to early stages of development. However,
emerging evidence has placed aberrantly expressed Ror2, lead-
ing to an invasive phenotype, in several cancers including renal
cell carcinoma (RCC). Although Ror2 is currently identified as
up-regulated in an assortment of cancers, neither the regulatory
role ormechanism of action have been delineated.We sought to
place Ror2 in themost commonlymutated pathway of RCC, the
loss of the tumor suppressor von Hippel-Lindau (VHL), which
causes hypoxia-inducible factor (HIF)-1 and -2 stabilization
and the transcriptional activation of a broad repertoire of
response genes.We found that Ror2 was indeed associated with
the pVHL loss in RCC as well as with VHL somatic mutations
tightly coordinated with the induction of RCC. Additionally,
knockdown and rescue analysis of HIF expression suggests that
Ror2 is dependent on pathologic stabilization of either HIF-1
or HIF-2. Subsequent evaluation of the ROR2 promoter sug-
gests that HIF-2 and its dimerization partner, aryl hydrocar-
bon nuclear transferase localize to the ROR2 promoter via a
cryptic transcriptional element. This data substantiates a
unique regulation pattern for Ror2 in theVHL-HIF axis that has
the potential to be applied to other cancer etiologies.
The tyrosine kinase Ror2 was initially identified as a homo-
logue of the Trk neurotrophin receptors (1) and later as amem-
ber of the receptor tyrosine kinase superfamily (2). Ror2 is an
orphan receptor with expression in the developing embryo
identified in the embryonic limb buds, heart, primitive genita-
lia, developing somites, and mesenchymal cells in the develop-
ing lung, kidney, and cephalic regions (3–5). In the adult orga-
nism, Ror2 expression is present as a part of osteoblast
differentiation, highly induced in the preosteoblast stage (6),
and is suppressed as these cells terminally differentiate as osteo-
cytes. This pattern of expression is inversely related to that of
secreted frizzled related protein 1 (sFRP1), and can be tran-
scriptionally suppressed by ectopic expression of sFRP1 in this
cell type, but further insights into the major elements of Ror2
regulation are not known.
Aside from developmental programs regulating bone mor-
phogenesis and primitive organ development, Ror2 has only
recently been recognized to play a role in the adult organism.
We have identified Ror2 expression as a characteristic of many
renal cell carcinoma (RCC)2 cell lines and human tumors (7),
where its expression is associated with increased cell migration
and anchorage-independent growth. Ror2 also plays a promi-
nent role in osteosarcoma (8) and has recently been identified
in squamous cell carcinoma of the head and neck, where
expression parallels the development of invasive features of
these tumors (9). Furthermore, in a tumor genomic analysis of
invasive gastric cancers, Ror2was identified as a frequent target
of mutagenesis (10). These findings place Ror2 as a frequently
up-regulated feature of human cancers, and in each case, is
associated with invasive tumor characteristics. Although Ror2
has been identified as a frequently overexpressed protein in a
variety of tumor types, the regulatory or mechanistic events
contributing to increased Ror2 expression in these tumors have
yet to be deduced.
Ror2 was initially identified as a renal tumor antigen in cell
lines derived from clear cell renal cell carcinomas that were
known to have inactivatingmutations of the vonHippel-Lindau
(VHL) tumor suppressor. Themajority of clear cell RCC tumors
are characterized by mutation, methylation, or loss of the VHL
gene (11–14). Themostwell documented function of the pVHL
protein is to act as the substrate recognition component of an
E3 ubiquitin ligase complex that includes Elongin C, Elongin B,
Cullin 2, and ring box protein 1 (Rbx1 or Roc1) (15–18). The
substrates of pVHL E3 ligase activity most tightly associated
with RCC are the hypoxia-inducible factor (HIF)- subunits
(HIF-1 and HIF-2), a family of transcription factors that
coordinate much of the physiologic response to restricted oxy-
gen availability (19–22). Under normal oxygen conditions, the
prolyl hydroxylases (PHDs) hydroxylate the HIF subunits,
which are subsequently recruited by pVHL to an E3 ubiquitin
ligase complex for ubiquitylation, leading to proteasomal deg-
radation (23–25). Under low oxygen conditions or as a result of
VHL inactivation, one or both of theseHIF factors are stabilized
leading to the formation of a transcriptional complex with aryl
hydrocarbon receptor nuclear translocator (ARNT, also known
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as HIF-1), inducing the transcription of a large panel of
hypoxia responsive genes including vascular endothelial
growth factor, glucose transporter 1 (GLUT1), prolyl hydroxy-
lase family member Egln3 (also known as PHD3), among many
others (26, 27). This transcriptional response leads to the highly
vascular phenotype of RCC and the transformed phenotype of
the cells (28).
VHL mutation is an important event in the development of
RCC, and activation of components of the HIF pathway can be
detected early in pre-malignant cysts that precede the develop-
ment of cancer in patients harboring a germline mutation in
VHL (29). However, within the spectrum of the VHLmutation,
tumors can demonstrate either stabilization of one or both of
these HIF factors, and may promote the transcriptional activa-
tion of certain subsets of the repertoire of hypoxia response-
induced genes (27). Additionally, the VHL mutational subtype
may itself mediate HIF expression patterns based on studies in
vitro (30), which parallel tumor growth in vivo (31). In particu-
lar, examination of human RCC tumors has demonstrated that
the molecular profile of tumors is highly dependent on the
expression of HIF-1 and HIF-2 in comparison to those tumors
solely expressing HIF-2, with distinctions that correlate with
divergent tumor activity (32).
Although VHL mutation and HIF dysregulation have been
identified as major contributors to the RCC tumor phenotype,
the specific molecular mechanisms associated with this path-
way that contribute to RCC features of cell growth, invasion, or
metastasis remain an active area of investigation. Thus, we
sought to examine the potential that Ror2 regulation was
occurring as a part of the VHL/HIF axis in RCC.We found that
Ror2 expression was definitively associated with the loss of
pVHL as well as with VHL mutations most tightly correlated
with HIF-2 dysregulation. Knockdown analysis and rescue
experiments suggest that Ror2 is dependent on the pathologic
stabilization of eitherHIF-2 orHIF-1 expression, although it
is not expressed as a component of the physiologic response to
hypoxia. This finding prompted an examination of the ROR2
promoter, which suggests that HIF-2 and ARNT are localized
to the ROR2 promoter, potentially utilizing a cryptic element
for its interaction. Coupled with observations that Ror2 has
been shown to be involved in the invasive tumor phenotype of
RCC and other malignancies, this study places Ror2 in the
VHL-associated HIF transcriptional pathway associated with
VHLmutation-mediated stabilization of HIF factors providing
support for a model where the spectrum of HIF target genes
activated as a result of the VHL mutation may contribute sub-
stantially to the phenotype of an individual tumor.
EXPERIMENTAL PROCEDURES
Antibodies—Both monoclonal and polyclonal antibodies
against Ror2 were obtained from R&D Systems (Minneapolis
MN). Antibodies against HIF-2 and Ku80 (loading control)
were obtained from Genetex (San Antonio, TX). The HIF-1
antibodywas obtained fromBDTransductions (Franklin Lakes,
NJ) and the Glut1 and Egln3 antibodies were obtained from
Novus Biologicals (Littleton, CO). For Figs. 3B and 5, a HIF-2
antibody obtained from R&D Systems was used for analysis.
Chromatin Immunoprecipitation Analysis—Cells were grown
to 80% confluence before being cross-linked with 11% formal-
dehyde. The cross-linked DNAwas then sonicated. Chromatin
immunoprecipitation analysis was performedwithHIF-1 (BD
Transduction), HIF-2 (R&D Systems), and ARNT1 (Novus
Biologicals). The resulting chromatin immunoprecipitated
DNA was analyzed by PCR using primers targeting the known
hypoxia response element region of Egln3/PHD3 (reverse
primer, 5-TAGGCACAGTAAACAGGCCC-3; forward
primer, 5-AGCGTCCGTTCCCAGCTCAG-3) as previously
described (35) as positive controls to validate the system. Addi-
tionally, primers were designed to target the 1-kb region of the
ROR2 promoter: primer A (reverse primer, 5-ACGCGCTTG-
TCCCCACCGAC-3, forward primer, 5-CTGCACTGCGC-
ACCGGGACA-3); primer B (reverse primer, 5-CGCTCTG-
GGCGCCTCTCCT-3, forward primer, 5-AGGAGC-
TGGGGCTGCAGCTGGG-3), primer C (reverse primer, 5-
AGCCCGCGCCAAGGAACCTC-3; forward primer, 5-
ACGATGCGTCCGCTCCTCCT-3), and primer D (reverse
primer, 5-TCTGGCGTTCCGGCTTGTGC-3; forward
primer, 5-CGTCGGGCGAGATGCGAATGG-3).
Cell Culture and Cell Treatments—The 786-0 cell line and
their paired derivatives, WT8 and RC3 (kindly provided by Dr.
W. Kaelin, BostonMA), the 786-0 VHL point mutant knock-in
cell lines and the RCC4 paired cell lines, 3-14 and 2-1 (kindly
provided byDr.M.C. Simon andDr. B. Keith, Philadelphia, PA)
were maintained in Dulbecco’s modified Eagle’s medium with
10% fetal bovine serum, L-glutamine, and nonessential amino
acids. For treated cells, the following conditions were utilized:
cobalt chloride (CoCl2) (Thermo Sci AcrosOrganics, Geel, Bel-
gium) was used at 100 M for the specified times, dimethylox-
alylglycine (DMOG) (CaymanChemical Company, AnnArbor,
MI) at 1 mM for 24 h, or cells were incubated under conditions
of 1% hypoxia for the specified times.
Immunoblot Analysis—Proteins were extracted from cul-
tured cells using cell lysis buffer consisting of 20 mM Tris, 100
mMNaCl, 1 mM EDTA, 1%Nonidet P-40, and a protease inhib-
itor mixture (Roche Diagnostics). Samples were quantitated
using Bradford reagent to measure absorbance. 40–50 g of
protein samples were then separated on 8% SDS-polyacryl-
amide gels, transferred to nitrocellulose membrane (GE
Healthcare), and the proper horseradish-conjugated secondary
antibodies were used. Proteins were detected using the Amer-
sham Biosciences ECL-Plus System and visualized on autora-
diography film (ISC BioExpress, Kaysville, UT).
qRT-PCR—cDNA was made by reverse transcription from
0.5 g of total RNA (5PRIME Perfect Pure RNA Cultured Cell
Kit, Gaithersburg, MD) using oligo(dT) primers and the
SuperScript II RT-PCR reagents (Invitrogen). Commercially
available proprietary FAM-labeled primers (ROR2, EGLN3,
GLUT1,HIF-1,HIF-2, and -actin) were used for amplifica-
tion and the samples analyzed on the 7900H Fast Real Time
PCR System using the recommended cycle conditions (Applied
Biosystems, Foster City, CA).
Transfections and shRNA—shRNA knockdown cells were
generated by infecting cells with pRetroSuper (pRS) packaged
shRNA for HIF-2 (kindly provided by Dr. W. Kaelin, Dana
Farber Cancer Institute (33)). Cells were supplemented with
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puromycin in the medium to maintain the shRNA for stable
suppression. Rescue ofHIF-2 shRNAcell lineswere generated
transiently by using a HIF-2 (mutated double proline to ala-
nine, DPA) expressing plasmid in a pcDNA3 backbone (kindly
provided by Drs. B. Keith andM. C. Simon, University of Penn-
sylvania). RCC4 lentiviral knockdown cells were generated by
infecting the cells with pLL 5.0 packaged shRNA (with a GFP-
expressing tag) forHIF-1 andHIF-2 (kindly provided by Dr.
W. Kim, University of North Carolina) and GFP-positive cells
were selectively sorted via GFP expression levels by the Univer-
sity of North Carolina Flow Cytometry Core Facility.
StatisticalAnalysis—Aone-way analysis of variancewas used
to analyze the standardized Ct values with the specified qRT-
PCR target (ROR2, EGLN3, GLUT1, HIF-1, and HIF-2) as
the fixed constant. Verification of the one-way analysis of vari-
ance model was performed using a Kruskal-Wallis test, a non-
parametric statistical procedure, to compare the standardized
Ct values. Error bars represent mean  S.E. p values referenced
as are followed: *, p  0.05 and **, p  0.01.
RESULTS
Ror2 Expression in Clear Cell RCC
Is Dependent on VHL Status—Our
previous work has shown that Ror2
is expressed in RCC tumors and
RCC cell lines. However, the tumor-
igenic mechanism that contributes
to this aberrant regulation of Ror2
in RCC remained uncertain. Be-
cause pVHL expression is tightly
associated with clear cell RCC, and
the RCCcell lines inwhichRor2was
initially identified lack functional
pVHL expression, we sought to
evaluate the expression of Ror2 in
RCC cell lines in relation to the
pVHL status. Whole cell extracts
were examined by immunoblot for
Ror2 expression in two independent
sets of RCC cell lines. Ror2 was first
examined in the VHL mutant cell
line 786-0, stably transfected with
empty expression vector (786-0
RC3), confirming Ror2 protein ex-
pression demonstrated by two inde-
pendent antibodies targeting the
Ror2 extracellular domain. How-
ever, when pVHL expression was
restored by the addition of a HA-
tagged VHL cDNA (786-0 WT8),
Ror2 expression was undetectable
using either antibody (Fig. 1A). To
explore the nature of this regulation
as a transcriptional event or as a
consequence of protein stabiliza-
tion, the VHL-dependent expres-
sion of ROR2 in RCC was assayed at
the mRNA level using qRT-PCR.
TheVHL() 786-0 RC3 vector con-
trol cell line had significantly enhanced ROR2 expression of
transcript compared with the VHL() wild type 786-0 WT8
derivative cell line, for which no transcript was detectable (Fig.
1B), paralleling the protein levels.
To verify that the VHL-dependent regulation of Ror2
observed was not cell line specific, we utilized the RCC4 paired
cell line for further analysis. Our results showed that VHL-null
RCC4 cells stably transfectedwith vector (RCC4 2-1) expressed
Ror2, whereas RCC4 cells stably expressing an HA-tagged wild
type VHL cDNA (RCC4 3-14) displayed dramatically reduced
levels of Ror2 protein as detected by immunoblot (Fig. 1C). This
VHL dependence was also confirmed at the transcript level as
ROR2 mRNA was suppressed to a significant degree in the
VHL() cell line RCC4 3-14 compared with theVHL() coun-
terpart RCC4 2-1 (Fig. 1D). These findings confirm that Ror2
expression is VHL-dependent at both the protein and mRNA
levels suggesting a transcriptionally regulated mechanism of
Ror2 expression is involved in multiple RCC cell lines.
FIGURE 1. Ror2 is regulated by VHL status. A, Ror2 is expressed when VHL is mutated in the 786-0 paired cell
line. Whole cell extracts from 786-0 cells expressing (786-0 WT8) or lacking expression (786-0 RC3) of pVHL were
immunoblotted with monoclonal Ror2 antibody (Ror2(1)), polyclonal Ror2 antibody (Ror2(2)), and Ku80 anti-
body as a loading control (LC). B, Ror2 expression is regulated at the transcriptional level in the paired 786-0 cell
lines. qRT-PCR analysis data are normalized to -actin as an RNA internal standard and displayed as expression
levels relative to the pVHL expressing member of the cell line pair. Significant differences were observed as
ROR2 mRNA levels were suppressed in the VHL() cell line (light gray), relative to the paired vector-transfected
VHL() control (dark gray), **, p  0.0001. C, Ror2 is expressed when VHL is mutated in the RCC4 paired cell line.
Whole cell extracts from RCC4 cells expressing (RCC4 3-14) or lacking expression (RCC4 2-1) of pVHL were
immunoblotted with monoclonal Ror2 antibody (Ror2(1)), polyclonal Ror2 antibody (Ror2(2)), and Ku80 anti-
body as a LC. D, Ror2 expression is regulated at the transcriptional level in the paired RCC4 cell lines. qRT-PCR
analysis data are normalized to -actin as an RNA internal standard and displayed as expression levels relative
to the pVHL expressing member of the cell line pair. Significant differences observed as ROR2 mRNA levels were
suppressed in the VHL() cell line (light gray), relative to the paired vector-transfected VHL() control (dark
gray), **, p  0.0001. Error bars represent mean  S.E.
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As regulation of Ror2 by wild type pVHL protein was evident
at both the protein andmRNA levels, we also sought to evaluate
the expression of Ror2 using the tight genotype/phenotype cor-
relation seen with representative VHL mutations associated
with the variousVHL disease subtypes.We examined a panel of
VHL somatic pointmutants expressed in 786-0 cells, represent-
ative of the mutant VHL transgenes seen in the major subtypes
of VHL disease associated with cancer predisposition. VHL
Type 2B mutations are associated with the most diverse pres-
entation of VHL disease and are thought to be more highly
penetrant for the development of RCC. In these stable clonal
cell lines expressing representative pVHLproteins, overexpres-
sion of Ror2was detected by immunoblot only in the absence of
pVHL or in the presence of a representative mutant pVHL of
VHL disease, subtype type 2B (Fig. 2). This mutation, arginine
167 to glutamine (R167Q), has previously been associated with
HIF-2 stabilization similar in extent to the VHL() cells (30).
Furthermore, representative mutations of VHL disease sub-
types 2A, which displays minimal deregulation of HIF factors
and low risk for renal cell carcinoma and type 2C, which retains
complete regulation of HIF factors and produces no risk for
renal cell carcinoma, were completely able to reverse the aber-
rent Ror2 expression. This data ties the expression of Ror2 to
VHL mutation and to correlative genotype/phenotype VHL
regulation and its expression in RCC.
Minimal Induction of Ror2 under Hypoxic Conditions—The
findings that Ror2 expression was associated with VHL loss or
mutations associated with HIF deregulation suggested that
Ror2 expression was correlated with HIF-2 stabilization.
Thus, we asked if Ror2may be regulated by the cellular hypoxic
response. Multiple strategies were evaluated as stimulants of
HIF stabilization, including exposure to 1% hypoxia and treat-
ment with various hypoxia mimetics. We examined the Ror2
protein as a target of the hypoxic response by evaluating Ror2
protein levels by immunoblot in the 786-0 paired RCC cells
after treatment a 16–96-h stimulation with 1% oxygen, or
hypoxia mimetics CoCl2 and DMOG. HIF, Egln3, and Ror2
were highly expressed in cells lacking functional VHL expres-
sion levels, and were not further induced by CoCl2. In 786-0
cells rescued with wild type VHL (786-0WT8), we observed an
expected induction in HIF-2 levels and the concurrent induc-
tion of the well established hypoxia target Egln3 (a HIF-depen-
dent prolyl hydroxylase). However, Ror2 protein levels were at
most only minimally induced in the cell lines with functional
VHL (an example, using CoCl2 is shown in Fig. 3A).
As the primary event of hypoxia response signaling occurs at
the transcriptional level, the effects of induction of the hypoxia
transcriptional response were also examined using quantitative
RT-PCR. The HIF target EGLN3, as well as another established
HIF target, the glucose transporter (GLUT1), were used to
demonstrate the traditional effect of these treatments on
hypoxia response gene induction. In response to CoCl2 treat-
ment, we observed an appropriate and significant increase in
Egln3 mRNA after 24 h in RCC4 cells expressing a wild type
VHL (RCC4 3-14), which are known to display intact hypoxia
response signaling. However, no significant change was
observed in the levels of ROR2 transcript in response to this
treatment (Fig. 3B). A second, more potent, chemical mimetic
of hypoxia, the prolyl hydroxylase inhibitor DMOG, was tested
to determine whether maximal induction of this pathway may
be sufficient to generate an induction in ROR2 levels after 24 h
of treatment. Both control transcripts (GLUT1 and EGLN3)
were robustly induced in response to this treatment within the
786-0 WT8 cell line (with functional VHL) demonstrating a
functional hypoxia pattern of transcriptional response. Again,
the hypoxia mimetic, DMOG, failed to show a statistically sig-
nificant increase in total ROR2 transcript levels (Fig. 3B).
Therefore, although VHL inactivation is associated with the
dysregulated expression of Ror2, activation of the hypoxia
response by either potent chemical inducers or profound expo-
sure to low oxygen levels were not sufficient to engage either
transcript or protein expression of Ror2.
Ror2 Is Regulated by HIF-2 Expression—Because HIF-me-
diated transcriptional induction is critical to the role of VHL
mutation in RCC (28) and Ror2 expression was increased at the
transcriptional level in aVHL-dependentmanner, we sought to
further evaluate whether Ror2 expression shared any associa-
tionwithHIF-dysregulation.As theVHL-deficient 786-0 cells
express only HIF-2, we used these cells to examine the linkage
between HIF stabilization and HIF-dependent transcriptional
regulation of Ror2 by suppressing HIF-2 in 786-0 cells with
two independent shRNA constructs (shRNA constructs kindly
provided byW. Kaelin, Dana Farber Cancer Institute (33)). Sta-
ble knockdown of the HIF-2 protein was achieved with both
shRNA constructs compared with a scrambled control shRNA.
Ror2 protein levels correlated linearly with HIF-2, being
markedly reduced when HIF-2 levels were suppressed by
shRNA (Fig. 4A). We additionally evaluated the effects of
HIF-2 knockdown on transcript levels. This experiment dem-
onstrated a reduction inHIF-2 transcript by shRNA suppres-
sion at or below the physiologic levels, and a corresponding
reduction in ROR2 mRNA with both shRNA vectors (Fig. 4B),
FIGURE 2. Expression of Ror2 in VHL somatic mutation subtypes. A panel
of VHL point mutant transgenes expressed in 786-0 cells, which recapitulate
the mutant VHL genes representative of the major subtypes of VHL disease,
was subjected to immunoblot analysis. There is graded HIF-2 expression
associated with the VHL mutations, with the greatest HIF-2 levels present in
cells expressing the VHL type 2B mutant and the vector-transfected cells that
lack pVHL expression. Expression of Ror2 is detected outside of the VHL null
cells only in the most penetrant subtype, VHL type 2B. Ku80 antibody used as
a loading control (LC).
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further implicating this pathway in the mechanism of Ror2
expression in RCC.
As we found Ror2 to be suppressed when HIF-2 was
knocked down, we also asked if Ror2 expression can be rescued.
Using aHIF-2 double proline to alanine (DPA) mutant cDNA
plasmid, which is resistant to hydroxylation andVHL-mediated
degradation (generously provided by B. Keith andM. C. Simon,
University of Pennsylvania), we examined 786-0 cells stably
expressing either of the HIF-2 shRNA constructs transiently
transfected with this HIF-2 DPA mutant. We observed tran-
sient rescue of high levels of HIF-2 expression in the 786-0
HIF-2 knockdowns and saw a delayed partial rescue of Ror2
correlated with the highest levels of HIF-2 rescue (Fig. 4C)
suggesting that Ror2 is expressed downstream of HIF-2 and
its expression is directly tied to HIF-2 expression in the con-
text of VHL inactivation.
Ror2 Is Regulated by Both HIF-1 and HIF-2 Expression—
Observing that Ror2 could be regulated by HIF-2, we also
explored the HIF-2-dependent
regulation in the context of concur-
rent HIF-1 stabilization and ex-
amined the more ubiquitously ex-
pressed HIF-1 subunit as a
potential regulator of Ror2 expres-
sion. Although many HIF-1 and
HIF-2 targets overlap, some are
dependent on only one or the other
subunit, HIF-1 or HIF-2, deriv-
ing the assumption that each of
these subunits may have unique or
context-specific functions (27). Uti-
lizing the RCC4 cell line, which
expresses both HIF-1 and HIF-2
subunits, we were able to examine
this proposition by suppressing
HIF-1 and HIF-2 independently
using a lentiviral shRNA system,
which included an iRESGFP for sta-
ble selection (lentiviral constructs
kindly provided byW. Kim, Univer-
sity of North Carolina). Transfect-
ing cells with lentiviral shRNA viral
particles with suppression titrated
by increasing GFP expression, we
observed that effective suppression
of HIF-1 and HIF-2 could be
achieved without nonspecific sup-
pression of the complementary HIF
proteins. However, as has been
observed previously, some positive
compensation in levels of the alter-
nate HIF factor was observed (32).
In particular, whenHIF-2was sup-
pressed, an increase in the basal lev-
els of HIF-1 were detected, al-
though the net cellular levels of HIF
appeared to be reduced. In this sys-
tem, which preserved the exclusive
deregulation of one HIF factor, we observed that Ror2 protein
levels were highly suppressedwhenHIF-2 levels were reduced
(Fig. 5A) andHIF-1were sustained, or even enhanced, further
implicating the HIF-2 pathway in the role of Ror2 regulation.
However, when HIF-1 protein levels were suppressed, partic-
ularly at the upper end of HIF-1 suppression, there was also a
measurable reduction in Ror2 protein expression (Fig. 5A), sug-
gesting that the regulation of Ror2 can also be influenced by
HIF-1 expression. Utilizing the most highly suppressed cell
line for each knockdown (based on selection for the highest
level of GFP expression), this phenomenonwas recapitulated at
the transcript level, demonstrating suppression of the ROR2
transcript with shRNA knockdown of either HIF-1 or HIF-2
(Fig. 5B). Additionally, simultaneous knockdown of both
factors produced an additive effect on ROR2 transcript
(supplemental Fig. S1). This observation that ROR2 transcrip-
tion is clearly linked to HIF stabilization, but that the mainte-
nance of one stabilized HIF factor fails to convey a functional
FIGURE 3. Minimal hypoxia induction of Ror2 expression. A, Ror2 expression is minimally induced after 48 h
of exposure to cobalt chloride. Normoxic (N) and CoCl2 (C)-treated protein samples were immunoblotted with
HIF-2 and Egln3 antibodies to show that HIF-2 and the HIF target Egln3 were induced in VHL() cell lines.
Ror2 levels remained stable to this manipulation. Ku80 antibody was used as a loading control (LC). B, left, ROR2
mRNA levels are minimally induced under hypoxic-like conditions in RCC4 cells. qRT-PCR analysis of the
hypoxia mimetic cobalt chloride (CoCl2) transcriptional induction after 24 h in the VHL expressing cell line RCC4
3-14 demonstrate induction of the HIF target gene EGLN3 (**, p  0.0015) in response to treatment with
hypoxia mimetic, confirming HIF transcriptional activity. Ror2 mRNA was not significantly induced under these
conditions. Right, Ror2 mRNA levels are minimally induced under hypoxic-like conditions in 786-0 WT8 cells.
qRT-PCR analysis of the hypoxia mimetic DMOG transcriptional induction after 24 h in the VHL expressing cell
line 786-0 WT8 demonstrate induction of HIF target genes EGLN3 (**, p  0.0091) and GLUT1 (**, p  0.0015) in
response to treatment with the hypoxia mimetic, confirming HIF transcriptional activity. Ror2 transcript levels
show minimal enrichment upon treatment. Transcript values are shown as normalized to the -actin RNA
internal standard and relative to the unstimulated cells of each set of paired cells. Error bars represent  S.E.
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redundancy, suggests that the overall amount of HIF present
in the cells influences the levels of Ror2 that are expressed.
These results imply that Ror2 expression is deregulated in can-
cer as a result of VHL inactivation and is dependent on sus-
tained or pathologically high level expression of eitherHIF sub-
unit, HIF-1 or HIF-2.
HIF Complex Localizes to the ROR2 Promoter—Observing
that Ror2 could be regulated by both HIF-1 and HIF-2, we
examined the ROR2 genomic sequence and untranslated
regions for evidence of a hypoxia response element that could
account for HIF-mediated transcriptional activation. None of
the previously reported canonical hypoxia response element
binding sites (5-CACGTA-3, or the degenerate sequence
5-BACGTSSK-3) were detected in the immediate proximity
of the ROR2 gene. Although isolatedmatching sites were found
throughout the sequence 10 kb upstreamand 2 kb downstream,
we decided to assess if HIF proteins could specifically interact
with the immediate 5 region of the Ror2 promoter. The
HIF-2 only expressing cell line 786-0was utilized for our stud-
ies. Chromatin immunoprecipitation, using HIF-1, HIF-2,
and ARNT/HIF-1 antibodies, was performed to analyze HIF
interactions with theROR2 promoter, utilizing four primer sets
covering a 1-kb region overlapping the transcriptional start site.
HIF-1 immunoprecipitation in this experiment was used as a
control, as this factor is not expressed in 786-0 cells. As a posi-
tive control, known primers targeting the hypoxia response ele-
ment of Egln3 (also known as PHD3) were utilized to confirm
HIF complex/chromatin interactions (35). We consistently
observed positive interactions with HIF-2 and ARNT in both
the EGLN3 control, as well as with primer set B and less consis-
FIGURE 4. Ror2 is regulated by HIF-2 expression. A, Ror2 expression is
suppressed in 786-0 HIF-2 shRNA knockdown cells. RCC cells expressing a
VHL transgene (786-0 WT8) were used to control for VHL-induced suppression
of Ror2. Cells lacking expression of VHL (786-0) were further transfected with
a control scramble shRNA (scramble) or a HIF-2 short hairpin RNA retrovirus
(shHIF-2) and immunoblotted with HIF-2, Ror2, and Ku80 (loading control,
LC) antibodies. B, ROR2 mRNA levels are suppressed in 786-0 HIF-2 shRNA
knockdown cells. qRT-PCR analysis of the 786-0 HIF-2 shRNA knockdown
cells verified effective HIF-2 knockdown in two independent knockdown
cell lines (**, p  0.0022, p  0.0001). Ror2 expression was concordantly sup-
pressed with HIF-2 knockdown (*, p  0.0172; **, p  0.0023). C, Ror2 expres-
sion can be rescued by HIF-2 overexpression. 786-0 cells stably expressing
scramble shRNA and shHIF-2 were rescued with transient expression of
empty vector (pcDNA) or proline hydroxylation-resistant double proline to
alanine HIF-2 mutant (DPA) for 48 and 72 h. Induction of Ror2 expression is
detected when HIF-2 expression is rescued with the DPA HIF-2 mutant in
the shRNA cell line. Error bars represent  S.E.
FIGURE 5. Ror2 is regulated by HIF-1 and HIF-2 expression. A, knock-
down of either HIF-1 or HIF-2 subunits suppresses Ror2 expression. Cells
constitutively expressing both HIF-1 and HIF-2 were subjected to lentiviral
shRNA of each subunit and sorted by GFP expression. Three populations
sorted for increasing GFP expression were assayed for each knockdown and
compared with a nonspecific sequence (shNS). When HIF-2 levels were sup-
pressed, HIF-1 levels remain constant, whereas Ror2 was down-regulated.
Similarly, when HIF-1 levels were highly suppressed and HIF-2 was stable,
Ror2 was also down-regulated. B, HIF-1 and HIF-2 knockdown each lead to
a loss of ROR2 expression. qRT-PCR analysis demonstrated effective shRNA-
mediated suppression of HIF-1 (**, p  0.0074; *, p  0.0165) or HIF-2 (**,
p  0.0002; *, p  0.0277). Ror2 expression is regulated by both HIF factors at
the transcriptional level (**, p  0.0002 HIF-1, p  0.0001 HIF-2). Error bars
represent  S.E.
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tently with primer set C in the ROR2 promoter (Fig. 6). A sec-
ond set of primers encompassing the same general region as
primer set Bwere designed, and also consistently demonstrated
a positive interaction (data not shown). Over multiple evalua-
tions, the A and D primers did not demonstrate an interaction
with HIF-2 or ARNT in these flanking segments of the ROR2
promoter (Fig. 6). These data suggest that we may have identi-
fied a cryptic site suitable of HIF complex binding in the imme-
diate promoter region of ROR2.
DISCUSSION
Ror2 is a developmentally regulated kinase normally
expressed in mesenchymal cells of organs such as the brain,
lung, heart, and kidney but is normally repressed in most adult
tissues, including the kidney (7). However, this kinase is dere-
pressed in a subset of human RCC tumors (7) as well as other
cancers (8–10), where it is emerging as a major factor promot-
ing tumor cell migration and tumor invasion phenotypes. We
sought to identify the mechanism of regulation for Ror2, con-
tributing specifically to its stable expression in RCC. The most
commonly referenced mutation in RCC pathology is of the
VHL gene, with over 70% of RCC tumors displaying inactiva-
tion of VHL leading to the subsequent stabilization of one or
more HIF factors, notably HIF-1 and HIF-2. The stabiliza-
tion of these potent transcriptional activators leads to the
expression of multiple hypoxia response genes responsible for
such phenotypes of renal tumors as prolific angiogenesis, cell
invasion, and metastasis (34).
We first observed that Ror2 was expressed in a VHL-depen-
dent manner in RCC. This was further corroborated by our
analysis of the VHL somatic point mutations that recapitulate
the VHL mutant transgenes that represent the major subtypes
of VHL disease. This analysis demonstrated that Ror2 is
expressedmost highly in the subtype thatmaintains expression
of the mutant VHL, but promotes the most significantly dereg-
ulated level of HIF-2 and is thought to lead to a highly pene-
trant form of RCC, type 2B. Furthermore, our work has previ-
ously shown that the VHL type 2B mutation, which was unable
to suppress Ror2 expression of VHL mutant cells, is dysregu-
lated for HIF-2 both in vitro (30) and in vivo (31). This ties
Ror2 to an important aspect of RCC tumorigenesis, as a poten-
tial contributor to invasive forms of this cancer. Furthermore,
this work linked Ror2 expression indirectly to dysregulated sta-
bilization of HIF, as Ror2 expression was observed in cell cul-
ture VHL somatic mutation models that produce either stabili-
zation of both HIF factors (VHL null), or the exclusive
stabilization of HIF-2 (VHL 2B).
Although the HIF- subunits share certain similarities, they
also have divergent responsibilities (27). As Ror2 has been
shown to beVHL-dependent and our data suggested a role for a
correlation with HIF stabilization, it provided a natural exten-
sion to analyze the independent effects of HIF-1 and HIF-2
subunits on Ror2 expression. Normally, transcriptional targets
that are unique to one of the HIF factors are not affected by
genetic repression of the uninvolved HIF factor. Additionally,
transcriptional targets that are mutual to HIF-1 and HIF-2,
such as GLUT1 or vascular endothelial growth factor, typically
require the depletion of both factors, due to transcription factor
compensation, to impact expression. We wanted to tease out
the difference in expression and analyze if exclusively one or
both HIF- subunits had an effect on Ror2 expression. Our
investigations point toward a clear correlation betweenHIF-2
stabilization and Ror2 expression in 786-0 cells, in which
genetic knockdown and rescue experiments confirm this linear
association. In cells expressing both HIF-1 and HIF-2, the
depletion of either factor was sufficient to reduce Ror2 expres-
sion at the transcript and protein levels. This suggests that with
graded suppression of either HIF-1 or HIF-2, Ror2 is coor-
dinately expressed in a similar manner, and that functional
redundancy between the factors may be dose-dependent. Such
a pattern of regulation is not typical of most transcriptional
components of the hypoxia response pathway, although similar
patterns of atypical regulation have been previously reported
for HIF targets (27). In the case of Ror2, the depletion of either
factor from the maximally stabilized state causes the loss of
Ror2 expression, indicative of a dosage effect of HIF factors on
transcriptional activation of ROR2.
Prior hypoxia target investigations suggest that the Ror fam-
ily ortholog cam-1 is a HIF-dependent hypoxia target in Cae-
norhabditis elegans (35). However, although the HIF pathway
has been studied extensively, Ror2 has yet to be identified as a
target of the hypoxia response pathway in mammalian cell
screens. Activation of the hypoxia response pathway via stabi-
lization of one or both of the HIF- subunits is a commonly
observed phenotype in RCC tumors, and physiologic up-regu-
lation of HIF factors as a result of strict decreases in oxygen
availability is an important cellular process in a variety of dis-
ease states.We thus extended our analysis to address this issue.
Despite the observation of clear linear connections between
FIGURE 6. HIF-2 and ARNT interact with the ROR2 promoter. Cells lacking
expression of VHL and overexpressing only HIF-2 (786-0) were subjected to
chromatin immunoprecipitation with HIF-1 (used as a negative control),
HIF-2, and ARNT antibodies. Primers were designed targeting the 1-kb
region of the Ror2 promoter that overlaps the Ror2 start site. Using primers
targeted against the promoter region containing a known hypoxic response
element of PHD3, also known as EGLN3, we show that HIF-2 and its dimer-
ization partner, ARNT, interact with the PHD3 promoter as expected. HIF-1
interaction is not detected, as this cell line does not express HIF-1. When the
ROR2 promoter was examined, HIF-2 and ARNT were localized to ROR2 pro-
moter regions B and C similarly to the control promoter. Interaction was not
observed for flanking regions A and D.
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HIF stabilization and Ror2 expression, we observed minimal
induction of Ror2 expression in these studies, even after pro-
longed exposure to hypoxia, or chemical poisoning of the prolyl
hydroxylation activitywith potent inhibitors. Thesedata suggest
that within the context of this tumor cell system, physiologically
relevant exposure to hypoxia may not be sufficient to induce
changes in Ror2 expression levels compared with normoxic con-
trols. This surprising result may shed further light on the mecha-
nism of Ror2 regulation as a cancer-associated kinase. Sustained
oncogenic levels of HIF factors are not routinely attained in
response to hypoxic insult. However, in renal cell carcinoma, as a
result of VHL inactivation, or in other tumors, notably squamous
cell carcinoma of the head and neck, HIF is induced to high con-
stitutive levels, whichmay account for the identification of a novel
HIF target associated with cancer.
Whether it is the distinctly high levels of HIF factors associ-
ated with VHL loss or the maintenance of high levels for sus-
tained periods of time that contributes toRor2 expression is not
certain. However, constitutive stabilization of HIF factors
occurs broadly across many types of tumors, such that Ror2 as
a tumor-associated kinase may be encountered even more fre-
quently. One potential reason hypoxia may fail to up-regulate
Ror2 expression is that ROR2 transcriptional regulationmay be
steps removed from HIF induction. Certainly several factors
downstream of HIF activation could be considered as interme-
diate transcriptional regulators of the expression of ROR2,
although which of these factors may contribute to regulation of
Ror2 expression either developmentally or in the tumor physi-
ology scenario remains to be determined.However, in our anal-
ysis of the ROR2 promoter, we found that HIF-2 and ARNT
can be localized to a small region of the immediate ROR2 pro-
moter region, which lacks any known hypoxia response ele-
ment binding sequence. This interaction of the HIF complex at
a cryptic ROR2 promoter site is suggestive of a direct mecha-
nismofHIF regulation.However, this finding does not preclude
the possibility that one or more additional transcriptional co-
factors may be required to coordinate activation in a manner
that is dependent onVHL loss orHIF stabilization, or thatmore
distant conserved hypoxia response element sites may be uti-
lized for HIF-dependent transcriptional regulation.
An additional possibility exists to link the dependence on
VHL inactivation and HIF stabilization in clear cell renal cell
carcinoma, and the failure of Ror2 to exhibit hypoxic induction.
VHL mutation also mediates alternate effects on cell signaling
external to thewell studied effects onHIF regulation. For exam-
ple, pVHL is known to affect the stabilization of a non-HIF-
associated protein, JADE-1 (36), and in a sophisticated genetic
screen inC. elegans, at least fourHIF-independent butVHL-de-
pendent genes were identified (37). Thus, our results may
reflect the activation of a gene that isHIF-dependent only in the
setting of a VHL mutation because of other context specific
cues. Furthermore, patterns of tumor cell invasion have been
suggested to be dependent on aspects of VHL loss that are not
clearly dependent on HIF stabilization. The extent to which
Ror2 may play a role in promoting these invasive features of
tumors will need to be further investigated.
RCC is a difficult to treat cancer that has few effective options
for treatment.We previously reported that Ror2 expression has
a distinct role in RCC tumor cell biology (7) and has the poten-
tial to be important for components of tumor invasion. We
have since demonstrated a mechanism of Ror2 regulation that,
with respect to clear cell RCC, can be linked to VHL loss and is
a component of the HIF-dependent transcriptional program in
clear cell RCC cell lines. This sustained stabilization of HIF is a
feature ofmany tumors, some ofwhich are independent ofVHL
mutation and are associated with advanced disease. Here we
offer a unique mechanism of regulation that offers insight into
howRor2 is deregulated in RCC that has the potential for appli-
cation in many other cancers.
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